Imel Biotherapeutics, Inc. — Form D
Imel Biotherapeutics, Inc. of WALTHAM, MA, a company, filed a Form D exempt-offering notice with the SEC on 2021-11-15. The offering totals $20.0M, of which $15.0M was reported sold. Industry: Other Health Care.
Offering
- Filed: 2021-11-15
- Form: D
- Accession: 0001893917-21-000001
- Industry: Other Health Care
- Exemptions: 06b
- Total offering: $20.0M
- Amount sold: $15.0M
- Remaining: $5.0M
- Investors: 5
- Date of first sale: 2021-10-29
- Security types: equity
- Revenue range: Decline to Disclose
- SEC file number: 021-421205
Issuer
- Name: Imel Biotherapeutics, Inc.
- CIK: 0001893917
- Entity type: Corporation
- Jurisdiction: DELAWARE
- Incorporated: 2019
- Address: 303 WYMAN STREET, SUITE 300, WALTHAM, MA, 02451
- Phone: 972-544506092
Officers, directors & promoters (5)
| Name | Role | Location |
|---|
| Taro Inaba | Director | TOKYO, M0 |
| Tomer Kariv | Director | Waltham, MA |
| Silvia Noiman, Ph.D. | Director | Waltham, MA |
| Silvia Noiman, Ph.D. | Executive Officer | Waltham, MA |
| Dori Pelled | Executive Officer | Waltham, MA |
More